Genenta Science S.p.A. (GNTA)
4.10
-0.13 (-3.07%)
At close: Jan 15, 2025, 3:58 PM
4.09
-0.24%
After-hours Jan 15, 2025, 03:59 PM EST
Company Description
Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy.
The company's lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.
It is also developing Temferon for use in the treatment of other solid tumor indications, locally advanced hepatocellular carcinoma, and intra-hepatic cholangiocarcinoma.
The company was incorporated in 2014 and is headquartered in Milan, Italy.
Genenta Science S.p.A.
| Country | IT |
| IPO Date | Dec 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Pierluigi Paracchi |
Contact Details
Address: Via Olgettina No. 58 Milan, Michigan IT | |
| Website | https://www.genenta.com |
Stock Details
| Ticker Symbol | GNTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001838716 |
| CUSIP Number | 36870W100 |
| ISIN Number | US36870W1009 |
| Employer ID | 00-0000000 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Pierluigi Paracchi | Co-Founder, Chairman & Chief Executive Officer |
| Richard B. Slansky | Chief Financial Officer |
| Barbara Regonini | Director of Finance |
| Dr. Bernard Rudolph Gentner M.D., Ph.D. | Co-Founder & Member of the Executive Scientific Board |
| Dr. Carlo Russo M.D. | Chief Medical Officer & Head of Development |
| Dr. Luigi Naldini M.D., Ph.D. | Co-Founder & Chairman of the Executive Scientific Board |
| Dr. Stefania Mazzoleni Ph.D. | Director of Program Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 30, 2024 | 6-K | Filing |
| Dec 20, 2024 | 6-K | Filing |
| Dec 20, 2024 | 424B5 | Filing |
| Dec 13, 2024 | 6-K | Filing |
| Nov 14, 2024 | 6-K | Filing |
| Oct 29, 2024 | 6-K | Filing |
| May 03, 2024 | 6-K | Filing |
| Apr 26, 2024 | 6-K | Filing |
| Apr 26, 2024 | 424B5 | Filing |
| Apr 08, 2024 | 6-K | Filing |